Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- 41 Financing Alzheimer’s Disease Drug Development
- 42 Valley of Death and the Role of Venture Philanthropy in Alzheimer’s Disease Drug Development
- 43 Alzheimer’s Association Funding and Policy for Alzheimer’s Disease Drug Development
- 44 The Role of Philanthropy in Alzheimer’s Disease Therapeutic Development
- 45 National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias
- 46 Alzheimer ’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study
- 47 Introduction to Venture Capital in Alzheimer’s Disease Drug Development
- 48 Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development
- Index
- References
41 - Financing Alzheimer’s Disease Drug Development
from Section 7 - Funding and Financing Alzheimer’s Disease Drug Development
Published online by Cambridge University Press: 03 March 2022
Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- 41 Financing Alzheimer’s Disease Drug Development
- 42 Valley of Death and the Role of Venture Philanthropy in Alzheimer’s Disease Drug Development
- 43 Alzheimer’s Association Funding and Policy for Alzheimer’s Disease Drug Development
- 44 The Role of Philanthropy in Alzheimer’s Disease Therapeutic Development
- 45 National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias
- 46 Alzheimer ’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study
- 47 Introduction to Venture Capital in Alzheimer’s Disease Drug Development
- 48 Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development
- Index
- References
Summary
Alzheimer’s disease (AD) is one of the biggest challenges to modern medicine. However, before February 2021, the last AD drug approval occurred in 2003, implying a 100% failure rate of AD therapeutic programs over the 17 years to that point; the lowest probability of success among all diseases. One of the key challenges is funding, which we explore in more depth in this chapter by first reviewing the current funding landscape for AD, and then considering the strengths and weaknesses of various commercialization strategies. Despite the discouraging track record of the biopharma industry in addressing AD, there is reason to be hopeful due to substantial scientific progress in developing a deeper understanding of the biology of the disease as well as increased federal funding for AD research. However, we also we need the private sector to translate these scientific breakthroughs into new medicines, which takes additional funding and new business models so as to reduce risk and improve returns for investors. If we can change the narrative of AD therapeutics to give investors new hope, the private sector can serve as a powerful partner to the biomedical community.
Keywords
- Type
- Chapter
- Information
- Alzheimer's Disease Drug DevelopmentResearch and Development Ecosystem, pp. 465 - 479Publisher: Cambridge University PressPrint publication year: 2022
References
Alzheimer’s Association. 2021 Alzheimer’s disease facts and figures. Alzheimers Dement 2021; 17: 327–406.CrossRefGoogle Scholar
PhRMA. Alzheimer’s medicines: setbacks and stepping stones. Available at: www.phrma.org/en/Alzheimer-s-Medicines-Setbacks-and-Stepping-Stones (accessed November 30, 2020).Google Scholar
Garde, D, Feuerstein, A. Why Biogen may be sitting on the most lucrative product in pharmaceutical history. Available at: www.statnews.com/2021/06/07/why-biogen-may-be-sitting-on-the-most-lucrative-product-in-pharmaceutical-history/ (accessed July 23, 2021).Google Scholar
Wong, CH, Siah, KW, Lo, AW. Estimation of clinical trial success rates and related parameters. Biostatistics 2019; 20: 273–86.Google Scholar
Wouters, OJ, McKee, M, Luyten, J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA 2020; 323: 844–53.Google Scholar
Scott, TJ, O’Connor, AC, Link, AN, Beaulieu, TJ. Economic analysis of opportunities to accelerate Alzheimer’s disease research and development. Ann N Y Acad Sci 2014; 1313: 17–34.Google Scholar
Cummings, JL, Morstorf, T, Zhong, K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014; 6: 37.Google Scholar
Prasad, V, Mailankody, S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 2017; 177: 1569–75.Google Scholar
Cleary, EG, Beierlein, JM, Khanuja, NS, McNamee, LM, Ledley, FD. Contribution of NIH funding to new drug approvals 2010–2016. Proc Natl Acad Sci USA 2018; 115: 2329–34.Google Scholar
US Department of Health and Human Services. National Plan to Address Alzheimer’s Disease. 2012. Available at: https://aspe.hhs.gov/national-plan-address-alzheimers-disease (accessed December 23, 2020).Google Scholar
National Institutes of Health. Estimates of funding for various research, condition, and disease categories (RCDC). 2020. Available at: https://report.nih.gov/funding/categorical-spending#/ (accessed July 19, 2021).Google Scholar
Mariotto, AB, Enewold, L, Zhao, J, Zeruto, CA, Yabroff, KR. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev 2020; 29: 1304–12.CrossRefGoogle ScholarPubMed
Keller, K, Briggs, L, Riley, E. Alzheimer’s disease: a center for strategic philanthropy giving smarter guide. Available at: https://milkeninstitute.org/sites/default/files/reports-pdf/FINAL-Alz-GSG2_2.pdf (accessed December 23, 2020).Google Scholar
Finkbeiner, S. Bridging the valley of death of therapeutics for neurodegeneration. Nat Med 2010; 16: 1227–32.CrossRefGoogle ScholarPubMed
Angel Resource Institute. Halo report: annual report on angel investments. 2020. Available at: https://angelresourceinstitute.org/ (accessed December 30, 2020).Google Scholar
Castiglia, O. Biotech angels bedeviled by dilution. Available at: www.forbes.com/sites/mergermarket/2020/01/06/biotech-angels-bedeviled-by-dilution/?sh=512e619c6486 (accessed July 19, 2021).Google Scholar
Fleming, JJ. The decline of venture capital investment in early-stage life sciences poses a challenge to continued innovation. Health Aff 2015; 34: 271–6.Google Scholar
National Venture Capital Association. NVCA and MedIC Coalition release patient capital 3.0: confronting the crisis and achieving the promise of venture-backed medical innovation. Available at: www.prweb.com/releases/2013/4/prweb10670100.htm (accessed December 30, 2020).Google Scholar
Thomas, D, Wessel, C. The state of innovation in highly prevalent chronic diseases. Volume IV: Alzheimer’s disease therapeutics. Available at: http://go.bio.org/rs/490-EHZ-999/images/BIO_HPCD4_ALZHEIMERS.pdf (accessed November 20, 2020).Google Scholar
PhRMA. 2020 PhRMA annual membership survey. Available at: https://phrma.org/Report/2020-PhRMA-Annual-Membership-Survey (accessed December 30, 2020).Google Scholar
Cole, MA, Seabrook, GR. On the horizon: the value and promise of the global pipeline of Alzheimer’s disease therapeutics. Alzheimers Dement (N Y) 2020; 6: e12009.Google Scholar
Fernandez, J-M, Stein, RM, Lo, AW. Commercializing biomedical research through securitization techniques. Nat Biotechnol 2012; 30: 964–75.Google Scholar
Lo, AW, Ho, C, Cummings, J, Kosik, KS. Parallel discovery of Alzheimer’s therapeutics. Sci Transl Med 2014; 6: 241cm5.CrossRefGoogle ScholarPubMed
Cummings, J, Lee, G, Ritter, A, Sabbagh, M, Zhong, K. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement (N Y) 2020; 6: e12050.Google Scholar
Fagnan, DE, Fernandez, J-M, Lo, AW, Stein, RM. Can financial engineering cure cancer? Am Econ Rev 2013; 103: 406–11.Google Scholar
Al Idrus, A. Dementia Discovery Fund reels in $350 M for disease-modifying drugs. Available at: www.fiercebiotech.com/dementia-discovery-fund-reels-350m-for-disease-modifying-drugs (accessed January 1, 2021).Google Scholar
Kim, E, Lo, AW. Venture philanthropy: a case study of the Cystic Fibrosis Foundation. Available at: https://ssrn.com/abstract=3376673 (accessed January 1, 2021).Google Scholar
Lo, AW, Naraharisetti, SV. New financing methods in the biopharma industry: a case study of Royalty Pharma, Inc. J Invest Manag 2014; 12: 4–19.Google Scholar
Chaudhuri, SE, Lo, AW. Financially adaptive clinical trials via option pricing analysis. J Econom 2020; DOI: 10.1016/j.jeconom.2020.08.012.Google Scholar
Eli Lilly. Lilly’s donanemab slows clinical decline of Alzheimer’s disease in positive Phase 2 trial. Jan 11, 2021. Available at: https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-slows-clinical-decline-alzheimers-disease (accessed January 18, 2021).Google Scholar
Kocahan, S, Zumrut, D. Mechanisms of Alzheimer’s disease pathogenesis and prevention: the brain, neural pathology, N-methyl-D-aspartate receptors, tau protein and other risk factors. Clin Psychopharmacol Neurosci 2017; 15: 1–8.Google Scholar
Sevigny, J, Chiao, P, Bussière, T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016; 537: 50–6.Google Scholar
Montazerhodjat, V, Chaudhuri, SE, Sargent, DJ, Lo, AW. Use of Bayesian decision analysis to minimize harm in patient-centered randomized clinical trials in oncology. JAMA Oncol 2017; 3: e170123.Google Scholar
Chaudhuri, SE, Ho, MP, Irony, T, Sheldon, M, Lo, AW. Patient-centered clinical trials. Drug Discov Today 2018; 23: 395–401.CrossRefGoogle ScholarPubMed
Isakov, L, Lo, AW, Montazerhodjat, V. Is the FDA too conservative or too aggressive? A Bayesian decision analysis of clinical trial design. J Econom 2019; 211: 117–36.Google Scholar
Chaudhuri, S, Lo, AW, Xiao, D, Xu, Q. Bayesian adaptive clinical trials for anti-infective therapeutics during epidemic outbreaks. Harvard Data Sci Rev 2020;DOI: https://doi.org/10.1162/99608f92.7656c213.Google Scholar
Chaudhuri, SE, Lo, AW. Incorporating patient preferences via Bayesian decision analysis. Clin J Am Soc Nephrol 2021; 16: 639–41.Google Scholar
Hauber, B, Mange, B, Zhou, M, et al. Parkinson’s patients’ tolerance for risk and willingness to wait for potential benefits of novel neurostimulation devices: a patient-centered threshold technique study. MDM Policy Pract 2021; 6: 2381468320978407.Google ScholarPubMed
- 1
- Cited by